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Programmed cell death-1 (PD-1) is a coinhibitory molecule 
and plays a pivotal role in immune regulation. Here, we 
demonstrate a role for PD-1 in pathogenesis of inflammatory 
bowel disease (IBD). Wild-type (WT) mice had severe wasting 
disease during experimentally induced colitis, while mice 
deficient for PD-1 (PD-1−/−) did not develop colon inflamma-
tion. Interestingly, PD-1−/− mice cohoused with WT mice 
became susceptible to colitis, suggesting that resistance of 
PD-1−/− mice to colitis is dependent on their gut microbiota. 
16S rRNA gene-pyrosequencing analysis showed that PD-1−/− 
mice had altered composition of gut microbiota with 
significant reduction in Rikenellaceae family. These altered 
colon bacteria of PD-1−/− mice induced less amount of 
inflammatory mediators from colon epithelial cells, including 
interleukin (IL)-6, and inflammatory chemokines. Taken together, 
our study indicates that PD-1 expression is involved in the 
resistance to experimental colitis through altered bacterial 
communities of colon. [BMB Reports 2017; 50(11): 578-583]
INTRODUCTION
The gastrointestinal tract of mammals and vertebrates is 
colonized by trillions of microorganisms that co-exist peacefully 
with the host, helping dietary digestion and protecting the host 
against rapid colonization of pathogens (1). Studies using 
germ-free animals have revealed that commensal microbiota is 
essential for development and function of competent immune 
systems in both periphery and intestinal mucosa (1, 2). When 
the acquisition or compositions of gut microbiota, however, 
are altered by genetic, environmental, or other unknown 
factors, these organisms are able to drive gut inflammation, 
leading to inflammatory bowel disease (IBD) (3). IBD is 
chronic inflammatory condition of the gastrointestinal tract, 
including Crohn’s disease (CD) and ulcerative colitis (UC). 
Although the precise pathogenesis of IBD has not been clearly 
elucidated, recent evidence has revealed that the aberrant 
immune activation against gut microbiota contributes to the 
pathogenesis of IBD (4, 5). In line with this, composition of gut 
microbiota is altered or abnormal in IBD patients (6-8).
Several lines of evidence indicate that T cells activated 
abnormally in the intestine are pathogenic effectors in IBD 
progress, resulting in secretion of proinflammatory cytokines, 
recruiting inflammatory cells, and gut injury (5, 9). Therefore, 
therapeutic strategies targeting T cell signaling, such as 
CTLA-4, have been evaluated to prevent activation of pathogenic 
mucosal T cells in IBD (10). In addition to CTLA-4, 
programmed death-1 (PD-1) is a negative costimulatory 
molecule, expressed on activated T/B cells and monocytes and 
exerts inhibitory functions via engagement with its ligand, 
PD-L1 (11, 12). In recent years, PD-1 has been studied for its 
regulatory function in T cell activation, immune tolerance, and 
autoimmunity, and considered as a potent therapeutic target for 
several autoimmune diseases (reviewed in ref. 13). Only few 
studies, however, report the role of PD-1/PD-L1 in intestinal 
inflammation (14, 15). An early study reports that PD-1 is 
highly expressed on T cells in inflamed colon from both IBD 
patients and colitic mice, and blockade of PD-L1 suppressed 
experimental colitis (14). Conversely, a recent study 
demonstrates gut epithelium-expressed PD-L1 as a key 
regulator of intestinal inflammation by inhibiting innate 
immune cells (15). Nevertheless, the role of PD-1/PD-L1 
pathway in the pathogenesis of IBD and the underlying 
mechanisms have not been extensively explored and remains 
largely unknown. In this study, we reveal that PD-1 deficiency 
alters composition of gut microbiota, thereby suppressing 
development of experimentally induced colitis.
RESULTS AND DISCUSSION
PD-1-deficient mice are less susceptible to DSS-induced 
colitis
To investigate the involvement of PD-1 in development of 
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Fig. 1. PD-1−/− mice are resistant to DSS-induced colitis. WT and 
PD-1−/− mice were given 2% (w/v) DSS in drinking water (DSS 
positive) or sterilized tap water (DSS negative) as a control. (A) 
Change in body weight (% of initial body weight, mean ± SEM) 
during DSS-administration. *P ＜ 0.05, **P ＜ 0.01 vs. DSS (-), 
WT mice; †P ＜ 0.05, ††P ＜ 0.01 vs. DSS (+), PD-1−/− mice 
by Student’s t-test. Data are pooled from three independent 
experiments. (B) Colon shortening of WT or PD-1−/− mice at 9 d 
after DSS-treatment. Each dot in the graph represents a single 
mouse. **P ＜ 0.01 by Student’s t-test. Data are pooled from 
two different experiments. (C) Histology of colons at 9 d (×400).
Histology score of DSS-treated WT (n = 5) and PD-1−/− mice (n 
= 5) were shown in the bar graph (mean ± SEM). ***P ＜
0.0001 vs. WT controls by Student’s t-test.
Fig. 2. Increased susceptibility to colitis of PD-1−/− mice by 
cohousing with WT mice. WT and PD-1−/− mice were cohoused 
(co-house positive) for 4 wks, and then were treated with 2% 
DSS for 9 d. (A) Change in body weight (% of initial body 
weight, mean ± SEM) during DSS-administration. Data are pooled 
from two independent experiments with similar results. *P ＜
0.05, **P ＜ 0.01 vs. single housed controls and †P ＜ 0.05 vs. 
WT, cohoused controls by Student’s t-test. (B) Colon shortening of 
mice at 9 d after DSS-treatment. Each dot in the graph represents 
a single mouse. Data are representative of two independent 
experiments with similar results **P ＜ 0.01, ***P ＜ 0.0001 by 
Student’s t-test. (C) Histology of colons at d 9. Histology score of 
DSS-treated WT (n = 4) and PD-1−/− mice (n = 6) were shown 
in the bar graph (mean ± SEM). **P ＜ 0.01, vs. single housed 
controls by Student’s t-test. 
colitis, we employed dextran sodium sulfate (DSS)-induced 
murine colitis model that mimics clinical and histological 
features of human IBD (16). Wild type (WT) and PD-1- 
deficient (PD-1−/−) mice were fed with 2% DSS in drinking 
water for 9 d, and parameters for colitis evaluation were 
determined. WT mice given 2% DSS showed time-dependent 
body weight loss (82.3 ± 2.2% of original weight at day 9), 
whereas PD-1−/− mice rarely lost their weight during DSS 
administration for 9 d (95.7 ± 0.9% of original weight at day 
9) (Fig. 1A). Concomitantly, colon shortening was not 
significantly observed in DSS-treated PD-1−/− mice, compared 
to DSS-fed WT mice (Fig. 1B). Histological analysis of colon 
from DSS-treated WT mice showed severe inflammation and 
infiltration of inflammatory cells, while the histological scores 
were significantly improved in DSS-fed PD-1−/− mice (Fig. 1C). 
In addition to its inhibitory effect on T cells, PD-1 negatively 
regulates the function of innate immune cells, as shown by 
down-regulation of cytokine production from macrophages 
upon PD-1 engagement (12) and elevated production of 
interleukin (IL)-12 from PD-1−/− dendritic cells (DC) (17). 
Consistently, we observed higher IL-12p40 production in 
laminar propria mononuclear cells (LPMC) from colon of both 
naïve and DSS-treated PD-1−/− mice, as compared to the WT 
control (Supplementary Fig. 1A). We previously showed the 
protective effect of IL-12p40 on DSS-induced colitis (18), thus 
we next examined whether higher production of IL-12p40 in 
PD-1−/− mice is critical for decreased incidence of colitis in 
PD-1−/− mice. We observed that treatment of neutralizing 
anti-IL-12p40 mAb into PD-1−/− mice during DSS administration 
did not exacerbate colitis in PD-1−/− mice (Supplementary Fig. 
1B). Although PD-1 has been demonstrated as an immune- 
inhibitory and anti-inflammatory molecule (13), our results 
indicate that PD-1 plays a pivotal role in the development of 
colitis, in which intestinal inflammation, unlike other auto-
immune diseases, may be regulated by distinctive mechanisms, 
independently of augmented cytokine production.
Co-housing PD-1-deficient mice with WT mice increases the 
susceptibility of DSS-induced colitis
It was shown that mice lacking certain components of the 
immune system have altered gut microbiota that can be 
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Fig. 3. Altered composition of colon microbial community in 
PD-1−/− mice. Bacteria in pooled cecal contents of WT and 
PD-1−/− mice were identified by 16S rRNA gen-pyrosequencing 
analysis (A) Average sequences per sample. Each bar represents a 
single sample pooled from 2 or 3 mice. (B) Shannon Diversity 
Index (mean ± SEM). (C) Venn diagram showing distributions of 
the shared OTUs. Taxon-based analysis at the level of (D) 
phylum, (E) family, and (F) species in bacterial composition 
between WT (white) and PD-1−/− mice (black) are shown as bar 
graphs. Data are pooled from three independent experiments, and 
each bar graph shows the abundance (%, mean ± SEM) in 
whole cecal bacteria. *P ＜ 0.05, **P ＜ 0.01 vs. WT controls 
by Student’s t-test.
Fig. 4. Colon epithelial cells produce less inflammatory mediators 
in response to cecal contents of PD-1−/− mice. (A) 1 × 105 of 
CT-26 cells were treated with cecal extract (CE) of pooled naive 
WT (n = 4) or PD-1−/− mice (n = 4) mice for 24 h. Expression 
of IL-6 in culture supernatant was measured by ELISA. (B) Colon 
lamina propria mononuclear cells (LPMCs) from DSS-untreated 
(DSS negative) or DSS-treated (DSS positive) mice were isolated 
and stimulated in vitro with CpG DNA for 24 h. IL-6 production 
in culture supernatant was measured by ELISA. The bar graph 
shows amount (mean ± SEM) of indicated cytokines (pg/ml). Data 
are pooled from three different experiments (n = 4 - 7 in each 
group). *P ＜ 0.05, **P ＜ 0.01 vs. WT controls by Student’s
t-test. (C) Relative mRNA level of chemokines was determined in 
CE-treated CT-26 cells, normalized by N32 expression. *P ＜ 0.05,
**P ＜ 0.01 vs. WT controls by Student’s t-test. Representative 
data (mean ± SEM) from two independent experiments are shown.
transmissible between mice and change susceptibility to 
intestinal inflammation (19-22). Kawamoto et al. showed that 
PD-1−/− mice exhibited alteration in their gut microbiota 
caused by impaired ability of follicular T helper (TFH) cells to 
select proper IgA precursor cells in Peyer’s patches in the 
absence of PD-1 (23). These studies led us to investigate 
whether the gut microbiota of PD-1−/− mice contributes to 
their non-colitogenic phenotype. To this end, WT mice were 
cohoused with PD-1−/− mice at 1:1 ratio for 4 wks and then 
treated with DSS in drinking water for 9 d. We found that 
PD-1−/− mice cohoused with WT mice had significant loss of 
body weight as compared to PD-1−/− mice housed alone, 
while the loss of body weight of WT mice was slightly 
ameliorated by cohousing with PD-1−/− mice, but was not 
statistically significant (Fig. 2A). In addition, cohoused 
PD-1−/− mice with WT mice showed colon shortening and 
extensive destruction of colon tissue, comparable to colitis- 
susceptible WT mice (Fig. 2B, 2C). These results suggest that 
resistance to DSS-induced colitis in PD-1−/− mice is 
dependent on their gut microbiota that is less colitogenic than 
those in WT mice.
Composition of gut microbiota is altered in PD-1-deficient 
mice
Since our data in cohousing experiment supports the previous 
report showing altered composition of microbiota in PD-1−/− 
mice (23), we next characterize microbial communities 
through 16S rRNA gene-pyrosequencing analysis with cecal 
contents of WT or PD-1−/− mice. We acquired 31,103 
sequences with an average ∼5,100 reads/sample (Fig. 3A). A 
total of 178 operational taxonomic units (OTUs) was obtained 
at 97% sequence identity, and Shannon Diversity Index was 
calculated for each sample to estimate the diversity of fecal 
microbiota. The diversity index of PD-1−/− mice was similar to 
that of WT mice (Fig. 3B), but the composition of gut 
microbiota based on the OTU distribution differed significantly 
between these two groups (Fig. 3C). PD-1−/− mice shared 51 
OTUs with WT mice, but had 56 unique OTUs. Taxon-based 
analysis indicated that microbiota in colon of WT and PD-1−/− 
mice was mainly composed of Bacteriodetes, Proteobacteria, 
Firmicutes, and Tenericutes (Fig. 3D). Interestingly, at the 
family level, Rikenellaceae was less abundant in PD-1−/− 
mice compared to WT mice (Fig. 3E). At the species level, 5 
species in major species (＞ 2% abundance) were significantly 
decreased in PD-1−/− mice compared to WT mice, among 
which 3 unculturable species (DQ815759_s, EF603419_s, 
EF097057_s) belonged to Rikenelleceae family, and other 
species is Helicobacter muridarum that was not detected in 
PD-1−/− mice (Fig. 3F). It was reported that enriched 
Rikenellaceae in IL-22−/− mice or high-fat diet-fed mice is 
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associated with intestinal inflammation (22, 24), and mono- 
association of H. muridarum in severe combined immuno-
deficiency (SCID) mice provoked intestinal inflammation in T 
cell transfer model of colitis (25, 26). Therefore, our results 
suggest that PD-1 deficiency resulted in altered composition of 
gut microbiota, which is associated with resistance to DSS- 
induced colitis. 
Colon epithelial cells produce less inflammatory mediators in 
response to cecal extracts from PD-1-deficient mice
To further determine whether colon microbiota of PD-1−/− 
mice is less colitogenic than WT commensal bacteria, we 
stimulated CT-26 colon epithelial cell lines with cecal extracts 
from WT or PD-1−/− mice. IL-6 production was significantly 
reduced in colon epithelial cells when stimulated with cecal 
contents from PD-1−/− mice (Fig. 4A), which indicates direct 
influence of altered microbiota on the production of 
inflammatory cytokine in epithelial cells. Consistently, 
decrease in IL-6 production was also observed in colon LPMC 
of PD-1−/− mice after DSS treatment (Fig. 4B). Again, the 
altered microbiota may play a role, albeit we may not rule out 
the possibility that the absence of PD-1 in LPMC also 
contributes to the production of cytokine. Production of other 
inflammatory cytokines, including TNF- and IL-1 was not 
significantly different between WT and PD-1−/− mice 
(Supplementary Fig. 2). Chemokines work as inflammatory 
mediators in various diseases mainly by recruiting immune 
cells to the site of inflammation. During IBD progress, 
expression of chemokines and their receptors increased, which 
include monocyte chemotactic protein 1 (MCP-1, CCL2) and 3 
(MCP-3), epithelial neutrophil activating protein 78 (CXCL5), 
macrophage inflammatory proteins 1 and 1 (MIP-1 and 
-1), interferon inducible protein 10 (IP-10, CXCL10), and 
fractalkine (CX3CL1) (27). Therefore, we analyzed an array of 
chemokines and found that expression of CCL2 and CXCL10 
was significantly reduced in colon epithelial cells in response 
to cecal extracts from PD-1−/− mice (Fig. 4C), which are 
known to be over-expressed in the colon of ulcerative colitis 
patients and play a participatory role in infiltration of effector 
cells into the inflamed tissues (28, 29). Thus, these results 
suggest that altered microbiota composition confers protection 
of PD-1-deficient mice from DSS-induced colitis by decreasing 
the production of inflammatory mediators. 
Role of intestinal microbiota in the pathogenesis of IBD has 
been highlighted for a recent decade. In this study, we reveal 
that PD-1−/− mice exhibit increased resistance to experimental 
colitis through altering composition of gut microbiota, which 
leads to reduction of inflammatory mediators in the colon. 
These findings are contrary to the well-known function of PD-1 
in terms of regulating immune activation and inflammation. 
Based on our 16S rRNA analysis, this unexpected role of PD-1 
in the DSS-induced colitis may be consequence of com-
plicated interplay between the mucosal immune system, 
epithelium, and the microbiota in the intestine, in which PD-1 
may exert its distinct effect on the development of colitis. 
Detailed mechanisms by which the altered microbiota in 
PD-1−/− mice modulates gut inflammation, with which types 
of immune cells are being targeted in the colon, remain to be 
further investigated. Moreover, our study also suggests that 
immune-modulatory activity via changing gut microbiota 
needs to be carefully considered, when we manipulate PD-1 
signaling, e.g. anti-PD-1 mAb or PD-L1-Fc protein, in various 
pathophysiological situations, including inflammatory diseases 
and cancer.
MATERIALS AND METHODS
Animal studies
Specific-pathogen-free C57BL/6 (B6) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME). PD-1−/− mice 
in B6-background were obtained from Dr. Tasuku Honjo 
(Kyoto University, Japan) via Dr. Sang-Nae Cho (Yonsei 
University, Korea). Mice were bred and maintained in the 
animal facility at the Pohang University of Science and 
Technology Biotech Center (Pohang, Korea), and 6- to 10-wk-old 
mice were used for all experiments. To induce colitis, B6 or 
PD-1−/− mice were fed with 2% (w/v) dextran sulfate sodium 
(DSS; m.w. of 36-50 kDa; MP Biomedicals, OH) in drinking 
water for 9 d. For cohousing experiment, female, 6-wk-old B6 
and PD-1 KO mice were housed together at a ratio 1:1 for 4 
wks prior to DSS administration.
Histology
Distal colon tissues were frozen sectioned and stained with 
H&E. Histological damage was scored as described with minor 
modification (30).
Preparation of lamina propria mononuclear cells (LPMCs)
At 9 d after DSS-administration, LPMCs in colons were isolated 
as described (31). In Brief, isolated colons were incubated in 
HBSS with 5% FBS and 2 mM EDTA (5% HBSS ＋ EDTA) and 
were digested in 5% HBSS with 1.5 mg/ml collagenase D and 
0.5 mg/ml DNase I (both from Roche Diagnosis, Indianapolis, 
IN) in 37oC for 40-50 min. 
Preparation of cecal extracts
For preparation of cecal extracts, frozen cecal contents from 
naïve B6 and PD-1−/− mice were thawed and well suspended 
in 5 volumes of sterile water. After centrifugation (4000 rpm, 
30 min), supernatant werewas collected and filtered through 
0.22 m filters. 
Analysis of inflammatory cytokine expression
1 × 106 cells/ml of LPMCs were stimulated with 1 M 
CpG-DNA 1668 (Invitrogen, Carlsbad, CA) for 24 h. In the 
other study, mouse epithelial cell line, CT-26, were cultured at 
1 × 105 cells in 190 l of RPMI ＋ 10% FBS with 10 l of 
cecal extracts for 24 h. The amount of cytokines in culture 
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supernatant was measured by ELISA. 
Meta 16S rRNA sequencing
Bacterial genomic DNA in cecal contents was extracted with 
FastDNA SPIN kit for soil (MP Biomedicals, OH) according to 
the manufacturer’s protocol. PCR was performed with Taq 
DNA polymerase and primers to the V1-V3 region of the 16S 
rRNA gene. Then, the amplified DNA was used as template for 
454 GS Junior (Roche Diagnosis, Indianapolis, IN) pyrose-
quencing (outsourced in ChunLab, Inc. Korea). Filter-passed 
3,000 reads were subjected to OTU (operational taxonomic 
unit) analysis with the cutoff similarity of 97% identity by 
using CLcommunityTM software.
Quantitative real time PCR
Total RNA from CT-26 cells was extracted by using 
ReliaPrepTM RNA Cell Miniprep System, and cDNA was 
synthesized by using GoScriptTM Reverse Transcription System 
(both from Promega, Fitchburg, WI). Quantitative Real-time 
PCR was performed with SYBR Green PCR Master Mix (Applied 
Biosystems, CA). The following primer sets were used: CCL2, 
5’-GCTGGAGCATCCACGTGTT-3’ and 5’-ATCTTGCTGGTGA 
ATGAGTAGCA-3’; CXCL2, 5’-CGCCCAGACAGAAGTCATAG- 
3’ and 5’-TCCTCCTTTCCAGGTCAGTTA-3’; CCL5, 5’-CACCA 
CTCCCTGCTGCTT-3’ and 5’-ACACTTGGCGGTTCCTTC-3’; 
CXCL9, 5’-TTTTGGGCATCATCTTCCTGG-3’ and 5’-GAGGTC 
TTTGAGGGATTTGTAGTGG-3’; CXCL10, 5’-CTTCTGAAAGG 
TGACCAGCC-3’ and 5’-GTCGCACCTCCACATAGCTT-3’; 
CCL11, 5’-GGCTGACCTCAAACTCACAGAAA-3’ and 5’-ACA 
TTCTGGCTTGGCATGGT-3’; LIF, 5’-ATGTGCGCCTAACATG 
ACAG-3’ and 5’-TATGCGACCATCCGATACAG-3’; L32, 5’- 
GAAACTGGCGGAAACCCA-3’ and 5’-GGATCTGGCCCTTGA 
ACC-3’.
Statistics
Data are typically shown as mean ± SEM. Differences between 
the groups were assessed using two-tailed Student’s t-test. A 
P-value of ＜ 0.05 was considered statistically significant.
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